MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Data Science_Biosimulation
Schrödinger, Inc. (NASDAQ:SDGR)*
Organization & Developments: Schrödinger
Parents
Schrödinger, Inc. (NASDAQ:SDGR)*
Children
*Schrodinger is a leading provider of computational software solutions that accelerate molecule discovery, design, and optimization. When coupled with AI, Schrodinger’s platform can evaluate billions of molecules per week versus 1,000s per year for traditional drug discovery approaches, greatly increasing the odds of finding a suitable molecule.
*Schrödinger is a life sciences and materials science company founded in 1990 that develops software for computational chemistry.
*Specializes in computational chemistry and drug design for the biopharmaceutical industry
2023: Schrodinger: Attractive Risk-Reward_seekingalpha.com
2023: Schrodinger: More Than An AI Bubble Stock
2024: Gates Foundation awards $10 million for predictive toxicology tools
2024: Gates Foundation awards second predictive toxicology grant
2024: Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
2024: Schrödinger Launches Initiative to Significantly Expand Application of Computational Tools for Predictive Toxicology
2024: Schrödinger Launches Initiative to Significantly Expand Application of Computational Tools for Predictive Toxicology
2024: Schrödinger, Inc. (SDGR): A Bull Case Theory
2024: Schrödinger, Inc. (SDGR): Among The Best Medical AI Companies
2024: Schrödinger, Inc. Continues To Be A Complicated Story
2024: Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024
2024: Schrodinger: More Drug Discovery Validation
2024: Schrödinger: Positive Signs Despite The Share Price Decline
2024: Schrödinger's Path Forward: AI, Cash Burn, And Clinical Uncertainty_ seekingalpha.com
2024: With $10M from Gates Foundation, Schrödinger Takes Aim at Toxicity Risk
2025: Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results
2025: Schrödinger: A Complex Story With Many Moving Part
2025: Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results
2025: Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)
2025: Schrödinger: Still Waiting On A Catalyst
2026: Schrodinger: AI Threat Is Looming Large (NASDAQ:SDGR)
Jumps
*Key People: Schrödinger
Finance & Acquisitions: Schrödinger